Abstract 420TiP
Background
EGFR TKIs are established as an effective treatment for patients with EGFRm+ NSCLC harboring common mutations (Del19 or L858R). However, 7% to 23% of NSCLC tumors harbor uncommon EGFR mutations, where EGFR TKI efficacy is less established. Up to 75% of patients treated with afatinib develop T790M resistance. Second-line osimertinib is highly effective in these patients. In the GioTag study, sequential afatinib and osimertinib was associated with encouraging outcomes (median TTF and OS: 28.1 and 41.3 months, respectively) in 203 patients who developed T790M mutations after first-line therapy in a real-world setting.
Trial design
This real-world, non-interventional, global, multi-center study (UpSwinG; NCT04179890) will enroll ∼400 patients with EGFR TKI-naïve advanced (stage IIIB/IV) EGFRm+ NSCLC treated with EGFR TKIs across ∼65 study centers in ≤11 countries. Pre-existing data will be retrospectively collected from medical records (paper or electronic); selection bias will be minimized where possible, including by selecting only consecutive patients meeting each of the inclusion criteria and none of the exclusion criteria. The study comprises two cohorts (∼200 patients each). Cohort 1 will include patients with tumors harboring uncommon or compound EGFR mutations who received first- or second-line EGFR TKI treatment. Cohort 2 will include patients with common EGFR mutations who progressed on first-line afatinib, tested positive for T790M and were subsequently treated with second-line osimertinib (40 or 80 mg/day). Key exclusion criteria include prior participation in other EGFRm+ NSCLC studies and patients with active brain metastases. Across both cohorts, the primary objective will be time on treatment, defined from the start of EGFR TKI treatment until the end of EGFR TKI treatment or death by any cause in cohort 1, and from the start of first-line until the end of second-line treatment or death by any cause in cohort 2. Secondary objectives include overall response rate, overall survival, and time on second-line treatment (in cohort 1). Thus far, 256 patients have been recruited: 206 in cohort 1, and 50 in cohort 2.
Clinical trial identification
NCT04179890.
Legal entity responsible for the study
Boehringer Ingelheim.
Funding
Boehringer Ingelheim.
Disclosure
S. Miura: Advisory/Consultancy, Speaker Bureau/Expert testimony: Chugai Pharma; Advisory/Consultancy, Speaker Bureau/Expert testimony: AstraZeneca; Advisory/Consultancy, Speaker Bureau/Expert testimony: MSD; Advisory/Consultancy, Speaker Bureau/Expert testimony: Lilly; Speaker Bureau/Expert testimony: Boehringer Ingelheim; Speaker Bureau/Expert testimony: Taiho Pharma; Speaker Bureau/Expert testimony: Ono Pharma; Speaker Bureau/Expert testimony: Bristol-Myers Squibb; Speaker Bureau/Expert testimony: Novartis; Speaker Bureau/Expert testimony: Abbvie; Speaker Bureau/Expert testimony: Kyowa Hakko Kirin. A. Märten: Full/Part-time employment: Boehringer Ingelheim. S. Popat: Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: BMS; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: Roche; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Takeda; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): AZ; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Pfizer; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: MSD; Honoraria (self), Advisory/Consultancy: EMD Serono; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Guardant Health; Honoraria (self), Advisory/Consultancy: AbbVie; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Boehringer Ingelheim; Honoraria (self), Advisory/Consultancy: Incyte; Honoraria (self), Advisory/Consultancy: Paradox; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution): Lilly; Research grant/Funding (institution): Ariad.
Resources from the same session
194P - Nab-paclitaxel plus capecitabine as first-line treatment for patients with recurrence or metastatic biliary tract cancer
Presenter: Jun Zhou
Session: e-Poster Display Session
370P - Bespoke circulating tumour DNA assay for the detection of minimal residual disease in esophageal adenocarcinoma patients
Presenter: Emma Ococks
Session: e-Poster Display Session
390P - A real-world clinical study of camrelizumab in the treatment of esophageal cancer
Presenter: Guoping Sun
Session: e-Poster Display Session
203P - Characterization of renal cell carcinoma (RCC) with VHL mutation
Presenter: Yanrui Zhang
Session: e-Poster Display Session
204P - Prospective observational study on pazopanib in patients treated for advanced or metastatic renal cell carcinoma (RCC) in Asia, North Africa and Middle East countries: Final analysis of PARACHUTE study
Presenter: Ravindran Kanesvaran
Session: e-Poster Display Session
205P - A study on organ preservation in muscle invasive urinary bladder cancer patients with intensity modulated radiotherapy and concurrent single agent cisplatin in south Indian population
Presenter: Himani Manchala
Session: e-Poster Display Session
206P - Mutational signature in urothelial carcinoma with TP53 mutation
Presenter: Huan Liu
Session: e-Poster Display Session
207P - Concordance of genomic alterations by next-generation sequencing in tumour tissue versus circulating tumour DNA in urothelial carcinoma
Presenter: wang Wang
Session: e-Poster Display Session
208P - Prognostic factors and outcomes of non-seminomatous germ cell tumours of testis: Experience from a tertiary cancer centre in India
Presenter: Lekha Nair
Session: e-Poster Display Session
210P - Prognostic value of sarcopenia in metastatic renal cell carcinoma patients: A systematic review
Presenter: Angeline Tancherla
Session: e-Poster Display Session